X-linked agammaglobulinemia diagnosed late in life: case report and review of the literature by unknown
BioMed CentralClinical and Molecular Allergy
ssOpen AcceReview
X-linked agammaglobulinemia diagnosed late in life: case report 
and review of the literature
Justin R Sigmon*, Ehab Kasasbeh and Guha Krishnaswamy
Address: Division of Allergy and Immunology, Department of Internal Medicine, East Tennessee State University, College of Medicine, Johnson 
City, Tennessee 37614, USA
Email: Justin R Sigmon* - jrsigmon@gmail.com; Ehab Kasasbeh - ehab_k78@hotmail.com; Guha Krishnaswamy - krishnas@mail.etsu.edu
* Corresponding author    
Abstract
Background: Common variable immune deficiency (CVID), one of the most common primary
immunodeficiency diseases presents in adults, whereas X-linked agammaglobulinemia (XLA), an
inherited humoral immunodeficiency, is usually diagnosed early in life after maternal Igs have waned.
However, there have been several reports in the world literature in which individuals have either
had a delay in onset of symptoms or have been misdiagnosed with CVID and then later found to
have mutations in Bruton's tyrosine kinase (BTK) yielding a reclassification as adult-onset variants
of XLA. The typical finding of absent B cells should suggest XLA rather than CVID and may be a
sensitive test to detect this condition, leading to the more specific test (Btk mutational analysis).
Further confirmation may be by mutational analyses.
Methods: The records of 2 patients were reviewed and appropriate clinical data collected. BTK
mutational analysis was carried out to investigate the suspicion of adult-presentation of XLA. A
review of the world literature on delayed diagnosis of XLA and mild or "leaky" phenotype was
performed.
Results: 2 patients previously diagnosed with CVID associated with virtual absence of CD19+ B
cells were reclassified as having a delayed diagnosis and adult-presentation of XLA. Patient 1, a 64
yr old male with recurrent sinobronchial infections had a low level of serum IgG of 360 mg/dl
(normal 736–1900), IgA <27 mg/dl (normal 90–474), and IgM <25 mg/dl (normal 50–415). Patient
2, a 46 yr old male with recurrent sinopulmonary infections had low IgG of 260 mg/dl, low IgA <16
mg/dl, and normal IgM. Mutational analysis of BTK was carried out in both patients and confirmed
the diagnosis of XLA
Conclusion: These two cases represent an unusual adult-presentation of XLA, a humoral
immunodeficiency usually diagnosed in childhood and the need to further investigate a suspicion of
XLA in adult males with CVID particularly those associated with low to absent CD19+ B cells. A
diagnosis of XLA can have significant implications including family counseling, detecting female
carriers, and early intervention and treatment of affected male descendents.
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Primary humoral immune deficiency disorders are charac-
terized by defects in antibody production leading to sig-
nificantly weakened humoral immunity. These patients
are highly susceptible to recurrent bacterial infections,
bacteremia, and sepsis resulting in high mortality rates.
Among these disorders there is heterogeneity of clinical
manifestations and immunological defects observed. Dif-
ferentiating one humoral immune deficiency syndrome
from another requires thorough immunological evalua-
tion in a timely fashion since early diagnosis and treat-
ment are essential to patient outcomes and survival. In
recent years, advances in genetic mutational analysis have
allowed physicians to more accurately diagnose patients
that present with recurrent infections and are suspected of
having an underlying primary immune deficiency. X-
linked agammaglobulinemia (XLA), although a disorder
of infants and children, sometimes may be diagnosed late
in life. In this instance, it may be easily confused for
another disorder-common variable immune deficiency
(CVID). Though the clinical and prognostic outcomes
may be considered to be similar in the two disorders, the
genetic basis is different, leading one to evaluate family
transmission more aggressively or consider gene therapy
as an option in one or more of these conditions.
We present two cases of XLA diagnosed late in life, and
review the clinical features and outcomes of similar cases
described in the world literature. CVID is one of the most
common primary immunodeficiency diseases requiring
medical treatment with a reported prevalence of 1 in
50,000 in the general population and usually presents in
adulthood[1]. XLA on the other hand is a recessive pri-
mary immunodeficiency disorder with a reported preva-
lence of 1/10,000 in the general population[1]. XLA is
associated with mutations in the Bruton's tyrosine kinase
(Btk) gene, which is integral to B cell signaling and matu-
ration. In patients with XLA, typically immunological
evaluation shows marked deficiency or absence of CD19+
B lymphocytes and severely decreased levels of all isotypes
of immunoglobulins, however wide variability in clinical
presentation among families with XLA have been
observed. In contrast to CVID, XLA is caused by a congen-
ital defect of B cell development and most often presents
during infancy after maternal Igs have dissipated, how-
ever, there have been several cases previously described in
which individuals had late onset of chronic infection or
were misdiagnosed with CVID and later found to have Btk
mutations [2,3]. Some of these cases highlight the hetero-
geneity of this disorder and may be related partially to the
extent of the genetic defect, associated B cell dysfunction
and apoptosis, or other poorly defined modifying factors.
Some of these patients with XLA presenting late in life
may represent a "leaky" or mild phenotype [4] as reviewed
later in the Discussion. In the two cases of XLA diagnosed
as an adult and described by us in this report, mutational
analysis demonstrated hemizygous Btk mutations. This
led us to subsequently reclassify the patients as having an
adult-presentation of XLA rather than CVID.
Methods
Approval was made by the institutional review board and
the records of two patients were reviewed and appropriate
immunological data collected. Peripheral blood lym-
phocyte and immunoglobulin enumerations were deter-
mined by flow cytometric analysis. Informed consent was
obtained from both patients for Btk mutational analyses
which were carried out by Correlagen Diagnostics labora-
tory in Worcester, Massachusetts. A review of the world lit-
erature for all cases of adult presentation of XLA was
performed using a PubMed search with MeSH terms/key-
words: XLA, X-Linked Agammaglobulinemia, atypical
XLA, adult and "leaky" or "mild" XLA.
Case Report
Patient 1
A 53-year-old male presented to the allergy and immunol-
ogy clinic for evaluation of hypogammaglobulinemia,
recurrent upper respiratory infections, recurrent bronchi-
tis, pneumonias, and urinary tract infections. Review of
his past medical history showed that at age 19 he was
diagnosed with bronchiectasis requiring a left lower lobe
lung resection and at age 23, he was diagnosed at Georgia
Tech as having hypogammaglobulinemia. Two years prior
to this diagnosis, his teenage brother was diagnosed as
having agammaglobulinemia and still receives intrave-
nous immunoglobulin. He received immunoglobulin
preparations intermittently after diagnosis of hypogam-
maglobulinemia which seemed to decrease the number of
infections. His last pneumonia was at age 20 and he has
had recurrent episodes of sinobronchial infections several
times per year since. His personal medical history also
revealed that he had pansinusitis and surgery for double
sinus windows around the age of 32. He also had a posi-
tive history for gastroesophageal reflux disease, prostatitis,
and hyperlipidemia. Physical exam yielded no relevant
findings other than the scar of lobectomy and expiratory
wheezing. No splenic enlargement or lymphadenopathy
was seen.
Laboratory results at his initial presentation revealed a
normal white blood cell count, low levels of serum IgG,
IgA, and IgM. Flow cytometric analysis showed zero
CD19+ B cells, normal CD4+ T cells, and elevated CD8+ T
cells (Table 1). Tests for anti-IgA antibody were compati-
ble with lack of anti-IgA antibodies. Serum protein elec-
trophoresis revealed no evidence of paraproteinemia. The
initial diagnosis was determined to be CVID and intrave-
nous immunoglobulin (IGIV) was started at a dose of 400
mg/kg of Gamimune every 4 weeks as a prophylacticPage 2 of 7
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hypogammaglobulinemic, demonstrated significantly
impaired functional responses to pneumococcal sero-
types, had a history of severe sinopulmonary disease
including pansinusitis and bronchiectasis requiring surgi-
cal resection, and to prevent further progression to severe
chronic obstructive lung disease. He continued to get reg-
ular IVIG infusions and maintained trough levels of IgG
above the lower end of normal (550 mg/dL).
At age 64 he was reevaluated and found to have signifi-
cantly decreased CD19+ B cells. This finding along with
his history of recurrent infection and a family history of
dysgammaglobulinemia prompted the decision to inves-
tigate the possibility of a Btk mutation. Informed consent
was obtained and Btk mutational analyses were con-
ducted. The results demonstrated a hemizygous point
mutation associated with a single amino acid change in
the pleckstrin homology (PH) domain of the Btk gene
(Table 2) consistent with a diagnosis of XLA.
Patient 2
A 42-year-old male presented to the allergy and immunol-
ogy clinic for evaluation of recurrent infections and sus-
pected immunodeficiency. From his personal medical
history it was revealed that he had onset of infections at
age 3 with a spinal meningitis followed by recurrent epi-
sodes of bronchitis, pneumonitis, and hospitialization
four times for pneumonia. Physical exam yielded no rele-
vant findings.
Laboratory results at his initial presentation revealed low
serum levels of IgG and IgA, with normal levels of IgM.
His flow cytometric analysis showed zero C19+ B cells,
normal CD4+ and CD8+ T cell counts, and low NK (natu-
ral killer cell) cell counts (Table 1). His total white blood
cell count was normal, as were polymorphonuclear cells,
but his lymphocytes were slightly decreased, and mono-
cytes were above reference range (Table 1). Anti-nuclear
antibody and rheumatoid factor were both negative.
Serum protein electrophoresis showed hypogammaglob-
ulinemia and no evidence of paraproteinemia. The total
serum protein and albumin levels were normal (Table 1).
His CH-50, C3, and C4 levels were within reference range,
but his pneumococcal responses were significantly
impaired.
Table 1: Results of immunological evaluation*
Patient 1 Patient 2
Age 64 46
WBC (cells/uL) 8.3 (3.2–9.8) 6.9 (5.0–10.2)
Granulocytes (%) 59 (42–75) 68 (45–75)
Lymphocytes (%) 28 (20–51) 18 (20–50)
Monocytes (%) 9.5 (0–12) 12 (0–8)
IgM (mg/dL) 25 95 (50–300)
IgG (mg/dL) 360 260 (565–1765)
IgA (mg/dL) 27 16 (40–350)
C3 (mg/dL) ND 129 (85–200)
C4 (mg/dL) ND 23 (14–53)
CH50 (U/ml) ND 51 (22–60)
CD4+ (cells/uL) 1023 (720–1440) 624 (575–1070)
CD8+ (cells/uL) 979 (315–788) 477 (190–860)
NK (cells/uL) ND 135 (150–880)
CD19+ (cells/uL) 0 (113–495) 0 (70–300)
SPEP Hypogammaglobulinemia Hypogammaglobulinemia
Pneumococcal responses Impaired Impaired
Abbreviations: SPEP, serum protein electrophoresis; WBC, white blood cells; NK, natural killer;
* Values in parentheses represent reference ranges
Table 2: Results of Btk mutational analysis
Patient 1 Patient 2
Nucleotide change c.83G>A c.1223T>C
Amino acid change p.Arg28His p.Leu408Pro
Domain PH SH1
Zygosity Hemizygous Hemizygous
PH, Pleckstrin Homology; SH1, Src homology 1Page 3 of 7
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unusual absence of CD19+ B cells prompted further eval-
uation for Btk mutations. At this time he was treated for
his current sinobronchial infection and classified as hav-
ing common variable immunodeficiency. IVIG was initi-
ated at a dose of 400 mg/kg of Gamimune every 4 weeks
as a prophylactic measure. During this time he main-
tained trough levels of IgG at or above 500 mg/dL and
reported having fewer sinobronchial infections requiring
antibiotics. Four years later, at the age of 46, he was reeval-
uated and informed consent was obtained and Btk genetic
mutational tests were conducted. The results demon-
strated a hemizygous point mutation associated with a
single amino acid change in the Src homology 1 (SH1)
domain of the Btk gene confirming a diagnosis of XLA
(Table 2). His nephew was recently diagnosed with
hypogammaglobulinemia and is being evaluated for XLA.
Discussion
Infantile and congenital immune deficiencies can present
in middle age or in the elderly and can be mistaken for a
variety of conditions such as atopy and CVID. Further test-
ing and evaluation may be required in such situations as
identification of a genetic and molecular defect will make
family screening easier, will allow potential gene therapy
in the future, and will also educate the patient about their
condition.
We present 2 cases of XLA diagnosed late in life in which
both patients were initially diagnosed as having CVID.
These patients presented with a history of recurrent upper
and lower respiratory tract infections requiring antibiotics
since childhood, but managed to survive into adulthood
without any acute life-threatening infections despite hav-
ing no replacement of immunoglobulins. Flow cytometric
analysis demonstrated absent CD19+ B cells and normal
CD4+ T cell numbers in both patients, but normal to ele-
vated numbers of CD8+ T cells. These findings along with
poor specific antibody responses to pneumococcal anti-
gens lead to genetic mutational analysis for Btk muta-
tions. Both patients were found to have hemizygous Btk
mutations, in the absence of mutations described with
CVID (such as TACI gene mutations). Since treatment of
patients with XLA or CVID is primarily to replace immu-
noglobulin and antibiotic therapy as needed, both
patients continued to receive IGIV at optimal doses and
have had moderate clinical improvement and reduction
of infections. We review below other reported incidences
of XLA presenting at an advanced age. These cases were
detected using a PubMed search of the world literature as
described under Methods.
Review of adult diagnosed XLA in the world literature
A review of the world literature revealed 16 cases of adult
presentation of XLA prior to these 2 cases which we
present (Table 3) [2-12]. Most of these patients were diag-
nosed during evaluation for recurrent pneumonia, sinusi-
tis, and otitis media infection and subsequently
diagnosed by Btk mutational analysis with XLA in adult-
hood. 5 patients were noted to have been previously diag-
nosed with CVID and later reclassified as atypical variants
of XLA. These patients ranged from 21 to 60 years of age
Table 3: Clinical data and Btk mutations of 16 patients reported in the world literature with atypical XLA.
Serum Ig level (mg/dL)* Btk Mutation
Patient no. Age (yrs)ϕ IgG IgA IgM Nucleotide Change Domain Reference
P1 51 401 <7 15 567C>A TH 12
P2 26 169 8 7 UD UD
P3 25 773 UD 1 UD UD 4
P4 34 420 UD UD UD UD
P5 27 635 <5 11 Glu605stop SH1 9
P6 40 <20 <20 22 G>Aψ NA 5
P7 39 220 UD UD W563L SH1
P8 60 429 7 14 994C>T SH2 6
P9 27 132 7 17 230C>T PH 10
P10 21 35 8 29 1630A>G SH1 8
P11 32 462 <8 <7 227T>C PH
P12 32 702 185 <25 1706G>A SH1
P13 28 454 95 38 UD UD 11
P14 27 346 16 8 1705C>T SH1
P15 24 NA 0 1 1942-1943del AG SH1
P16 31 527 8 30 UD UD
UD, Undetermined; NA, Not applicable
* Serum immunoglobulins reported at the age of diagnosis
ϕ Age at diagnosis
ψ Splice site mutation at the 3' end of intron 13: IVS 13 -1 G>APage 4 of 7
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prior to initiation of treatment with IGIV. The low to nor-
mal levels of IgG in many of these patients may partially
explain why symptoms in many of these patients were
mild or subclinical until diagnosis in adulthood. Marked
variation in the effects of each Btk mutation on the pro-
duction of functional Btk protein may account for the
presence of small numbers of immunoglobulin produc-
ing CD19+ B cells and a marginal ability to evade severe
infection through childhood in these patients.
Kornfeld et al described a case of extreme variation in a
three-generation family in which the proband, a 51 year
old male with recurrent sinusitis, was found to have atyp-
ical XLA as was a nephew whom was diagnosed upon con-
tracting pseudomonas bacteremia at age 10 months and
then died at age 8 from encephalitis [13]. This case dem-
onstrates the clinical variability of a XLA within a family
in which typical and atypical variants exist and the need
for maternal screening and early treatment of affected off-
spring.
Molecular Defect
XLA is caused by an arrest in B cell development associ-
ated with mutations in the Btk gene which has been
mapped to Xq21.3-q22. BTK is a member of the Tec fam-
ily of nonreceptor tyrosine kinases and is expressed
throughout B-cell development from CD34+ CD19+ pro-B
cells to mature B cells. Other cells express Btk including
erythroid precursors, mast cells, monocytes, myeloid cells,
megakaryocytes, and platelets, however its expression is
absent in T and natural killer cells [1]. Btk functions to
transduce signals from the B cell immunoglobulin recep-
tor (BCR) and absence of Btk has been shown to halt nor-
mal B cell development at the pre-B transitional cell stage
with premature induction of apoptosis. Btk signaling is
integral to the progression of pre-B1 cells to pre-B2 cells.
Btk promotes phosphorylation of residues in phospholi-
pase C gamma (PLCg) which in turn activates 1,4,5-tri-
phosphate (IP3) and diacylglycerol (DAG). These second
messengers ultimately promote movement of intracellu-
lar calcium and activation of protein kinase C (PKC).
PKCβ activation is key to the activation of NF-κB and sub-
sequent signaling needed for cell survival. Without suffi-
cient Btk protein, these pro-survival signals are not made
and the pre-B cells undergo immature apoptosis. In
patients with XLA, studies have shown pro-B and pre-B1
cells to comprise more than 80% of the bone marrow B
cell population compared with less than 20% in normal
individuals [1].
The Btk genome sequence consist of 19 exons and muta-
tions have been reported in all five of the domains of the
Btk gene including the Pleckstrin Homology (PH), Tec
homology (TH), Src homology 1 (SH1), Src homology 2
(SH2), and Src homology 3 (SH3). The PH domain is con-
sidered to be the most distinct and has crystal structure
similar to many other signaling proteins. The PH domain
consists of a positively charged ligand-binding pocket that
binds phosphatidylinositol lipids. This binding is neces-
sary to promote Btk translocation and localization to the
cell membrane [1]. Mutations in this domain such as the
hemizygous point mutation in our patient may inhibit
the signaling needed for recruitment of Btk to the cell
membrane where it functions to transduce signals from
the B cell receptor (BCR) of pre-B cells. The TH domain
contains of a proline rich region which interacts with SH3
domains and may have a regulatory function on other Tec
family members [14]. The SH domains of Btk are very
similar to classical Src tyrosine kinase domains. SH1 func-
tions as the catalytic kinase domain and the SH2 and SH3
domains are responsible for binding and interacting with
tyrosine-phosphorylated proteins and polyproline motifs
[1]. Mutations in each of these domains have been
described in patients with XLA, but no correlation
between onset and severity of specific mutations in these
patients have been described.
Mutations of Btk
According to Valiaho et al and their 2006 review of the
online mutation database for Btk mutations, BTKbase,
1,111 patient entries have been compiled from 973 unre-
lated families with 602 unique molecular events. Of all
these mutations 40% were missense mutations leading to
amino acid substitutions, premature stop codons, and
exon skipping, while the remainder consisted of 17%
nonsense, 20% deletions, 7% insertions, and 16% splice-
site mutations [15]. The distribution of mutations is rela-
tively proportional to the size of each of the five domains.
Our two cases had mutations in the PH and SH1 domains
(Table 2). From review of the world literature, 16 cases of
XLA with diagnosis delayed to adulthood were found.
Mutations were found in four of the five domains includ-
ing 2 PH domain mutations, 1 SH2 domain mutation, 1
TH domain mutation, 6 SH1 domain mutations, and 6
did not specify a domain. 8 of the 10 cases which specified
a domain were point mutations and 2 were deletions
(Table 3). There appears to be no direct correlation
between mutations in any specific domain with adult
presentation of XLA. Interestingly Saffran et al described
an SH2 domain mutation which allowed normal levels of
Btk transcript to be produced and encoded an unstable
protein in an individual with atypical XLA suggesting that
subtle mutations may block one pathway in the Btk sign-
aling cascade while other alternate pathways may con-
tinue to function [6]. Variation in severity of specific
mutations may account for "mild" phenotypic variants of
XLA allowing certain individual's CD19+ B cells to survive
long enough to produce sufficient amounts of immu-
noglobulins to avoid life-threatening infections in child-Page 5 of 7
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represent "mild" phenotypes of XLA despite having signif-
icantly low to absent B cells. Noordzij et al suggest that
these milder clinical phenotypes may be associated with
BTK splice-site mutations which produce lower levels of
wild-type BTK transcripts [4].
Differentiating XLA and CVID
Knowledge of the key characteristics of XLA and CVID
may assist in the differentiation of these two clinically
similar diseases (Table 4). XLA and CVID are both
humoral immunodeficiencies that can manifest similar
clinical presentations when encountering a patient in
their second to sixth decade as seen in our two cases. Dis-
tinguishing between XLA and CVID in a patient can have
significant implications when considering the morbidity
of affected males and their descendents. With the benefit
of technological advances in recent years, screening
female carriers and other male relatives, and genetic coun-
seling now serve pivotal roles in the healthcare of a family
with XLA. Table 4 discusses these differences in detail.
Conclusion
In conclusion, we present two males diagnosed in adult-
hood with CVID whom upon further investigation by BTK
mutational analysis were found to have XLA. These two
cases demonstrate delayed diagnosis and adult presenta-
tion of XLA which is usually diagnosed in the first decade
of life in male children with recurrent bacterial infections.
DNA sequencing of the BTK gene from each patient
showed mutations in the PH domain of patient 1 and the
SH1 domain of patient 2. Each of these mutations had
been previously reported in the BTKbase online registry.
Prior to these two patients, 16 other patients were
reported in the world literature with adult presentation of
XLA. Any male patient who presents with recurrent infec-
tions, hypogammaglobulinemia, and low to absent
CD19+ B cells should be suspected of having XLA. In atyp-
ical cases such as these two that we present, the virtual
absence of CD19+ B cells may be a sensitive test to differ-
entiate XLA from CVID, which may lead to the more spe-
cific genetic mutational analysis for Btk mutations.
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Table 4: Key characteristics of XLA and CVID
XLA CVID
Age of onset usually by 9–18 months usually 2nd – 4th decade
Family Hx of immunodeficiency usually +ve variable*
Inheritance x-linked recessive variable
Diagnosis
Lymph nodes/tonsils absent tonsillar tissue normal tonsillar tissue
CD19+ B cell numbers markedly decreased/absent normal/low
CD4+ T cell numbers Normal Variable**
CD8+ T cell numbers Normal Variable**
CD4+ CD8+ ratio Variable often decreased
Specific Antibody titers absent decreased/absent
Mutations reported Btk TACI, ICOS, BAFF-R, CD19+






Symptomatic care Symptomatic care***
*Some familial clustering has been described in the literature, possibly associated with Class II MHC gene complex
**CD4+ and CD8+ numbers may be low or normal
*** Symptomatic care includes antimicrobials, surgical drainage, nebulizer treatment for wheezing, allergy management, avoidance, nutrition, etc.
Abbreviations: TACI, Transmembrane activator and calcium-modulator and cyclophilin ligand interactor, Btk, Bruton's tyrosine kinase, ICOS, 
inducible costimulatory receptor, CEMA, chronic enteroviral meningoencephalitis, VAPP, vaccine-associated paralytic poliomyelitis, IGIV, 
intravenous immunoglobulin.Page 6 of 7
(page number not for citation purposes)
Clinical and Molecular Allergy 2008, 6:5 http://www.clinicalmolecularallergy.com/content/6/1/5Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
plied the manuscript outline and reviewed the manuscript
for final submission.
References
1. Stiehm E, Ochs HD, Winkelstein JA: Primary Immunodeficien-
cies.  In Immunologic Disorders in Infants and Children Edited by:
Fletcher J. Philadelphia: Elsevier Saunders; 2004:357-62. 
2. Hashimoto SMT, Futatani T, Kanegane H, Usui K, Nukiwa T,
Namiuchi S, Matsushita M, Yamadori T, Suemura M, Kishimoto T,
Tsukada S: Atypical X-linked Agammaglobulinemia Diag-
nosed in Three Adults.  Internal Medicine 1999, 38:722-5.
3. Stewart D, Tian L, Nelson DL: A Case of X-linked Agammaglob-
ulinemia Diagnosed in Adulthood.  Clinical Immunology 2001,
99:94-9.
4. Noordzij JG, de Bruin-Versteeg S, Hartwig NG, Weemaes CM, Ger-
ritsen EJ, Bernatowska E, van Lierde S, de Groot R, van Dongen JJ:
XLA Patients with BTK splice-site mutations produce low
levels of wild-type BTK transcripts.  Journal of Clinical Immunology
2002, 22:306-18.
5. Morwood K, Bourne H, Philpot R, Gold M, Gillis D, Benson EM: Phe-
notypic variability: Clinical presentation between the 6th
year and 60th year in a family with x-linked agammaglob-
ulinemia.   J Allergy Clin Immunol 2004, 113(4):783-5.
6. D Saffran OP, M Fitch-Hilgenberg, et al.: A Point Mutation in the
SH2 Domain of Bruton's Tyrosine Kinase in Atypical X-
linked Agammaglobulinemia.  New England Journal of Medicine
1994, 330:1488-91.
7. Lin M, Chien Y, Shyur S, Huang L, Chiang Y, Wen D, Liang P, Yang H:
De novo mutation in the BTK gene of atypical X-linked
agammaglobulinemia in a patient with recurrent pyoderma.
Annals of Allergy, Asthma, and Immunology 2006, 96:744-8.
8. Usui K, Sasahara Y, Tazawa R, Hagiwara K, Tsukada S, Miyawaki T,
Tsuchiya S, Nukiwa T: Recurrent pneumonia with mild hypog-
ammaglobulinemia diagnosed in X-linked agammaglob-
ulinemia in adults.  Respir Res 2001, 2:188-92.
9. Mitsui T, Tsukamoto N, Kanegane H, Agematsu K, Sekigami T, Irisawa
H, Saitoh T, Uchiumi H, Handa H, Matsushima T, Karasawa M,
Murakami H, Miyawaki T, Nojima Y: X-linked agammaglobuline-
mia diagnosed in adulthood: a case report.  Int J Hematol 2006,
84:154-7.
10. Kanegane H, Miyawaki T, Wang Y, Nomura K, Shinozaki K, Matsukura
H, Kubota T, Tsukada S, Miyawaki T: Clinical and mutational
characteristics of X-linked agammaglobulinemia and its car-
rier identified by flow cytometric assessment combined with
genetic analysis.  J Allergy Clin Immunol 2001, 108(6):1012-20.
11. Bulley S, Zhang J, Kwong S, Roifman C: Newly diagnosed X-linked
Agammaglobulinemia, Bruton's Tyrosine Kinase (BTK)
Mutation, in a 39 Year-Old Male.  Journal of Allergy and Clinical
Immunology 2002, 109:S188.
12. Kornfeld S, haire RN, Strong SJ, Tang H, Sung SJ, Fu SM, Litman GW:
A Novel Mutation (Cys145Stop) in Bruton's Tyrosine Kinase
Is Associated with Newly Diagnosed X-linked Agammaglob-
ulinemia in a 51-year-old Male.  Molecular Medicine 1996,
2:619-23.
13. Kornfeld S, Haire RN, Strong SJ, Brigino EN, Tang H, Sung SJ, Man Fu
S, Litman GW: Extreme variation in X-linked agammaglob-
ulinemia phenotype in a three-generation family.  Journal of
Allergy and Clinical Immunology 1997, 100:702-6.
14. Okoh M, Vihinen M: Interaction between Btk TH and SH3
domain.  Biopolymers 2002, 63:325-34.
15. Valiaho J, Edvard Smith CI, Vihinen M: BTKbase: The Mutation
Database for X-Linked Agammaglobulinemia.  Human Muta-
tion 2006, 27:1209-17.Page 7 of 7
(page number not for citation purposes)
